• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • English
    Chinese
    French
    Hindi

    Chemotherapy Market

    ID: 4335
    126 Pages
    Research Team
    02/2021

    Chemotherapy Market Research Report Information By Drug Class (Mitotic Inhibitors, Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors and Antitumor Antibiotic), By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Leukemia and Ovarian Cancer), By Route of Drug Administration (Intravenous, Oral, Subcutaneous, Intra-Muscular, Intravesi...

    Share:
    ReportInfographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License

    Market Summary

    Global Chemotherapy Market Overview

    Chemotherapy Market Valued at USD 8.9 billion in 2023, projected to grow from USD 9.6 billion in 2024 to USD 16.84 billion by 2032, exhibiting a CAGR of 7.40% during the forecast period (2024 - 2032). 

    Factors such as rising cancer prevalence, an increase in the number of sufferers receiving chemotherapy and radiotherapy treatments, an increase in compliance with chemotherapy drugs due to various treatment options, and the availability of combination therapies are the key market drivers enhancing the market growth. The market for chemotherapy is anticipated to expand due to advances in drug delivery, development, and the shift toward biologics.

    Chemotherapy Market Overview

    Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

    Chemotherapy Market Trends

      • Growing cancer rates are fueling the market growth

    Market CAGR for chemotherapy is driven by the rising number of cancer patients. Cancer incidence has climbed globally, overtaking cardiovascular diseases as the second greatest cause of death. This phenomenon is caused by environmental variables such as cigarette use, altered dietary habits, urbanization, and prolonged post-reproductive lifetime. For instance, the World Health Organisation (WHO) estimates that there will be 29.4 million new instances of cancer worldwide by 2040, up from 18.1 million in 2018. Therefore, it is anticipated that the rising incidence of cancer will increase the demand for oncology cancer medications globally throughout the projection period. Furthermore, the industry will benefit from the population's growing cancer awareness in the next years.

    Figure 1: Total estimated occurrence of different types of cancer in both type of genders in 2020

    Total estimated occurrence of different types of cancer in both type of genders in 2020

    Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

    Cancer treatment is developing more quickly than ever. Emerging from the research and development pipeline are several novel treatments frequently combined with other brand-new or current medications. Numerous pharmaceutical companies are funding these revolutionary medication development projects to treat cancer. For instance, Pfizer purchased Array BioPharma in June 2019, intending to expand its oncology footprint and pipeline, starting with a melanoma combination medication that has been licensed and is currently testing for metastatic colorectal cancer. This is expected to accelerate market expansion and grow consumer desire for biosimilar and biologic products.

    Another significant element influencing the growth rate of the market for chemotherapy is the rising cost of healthcare, which contributes to the development of its infrastructure. Government organizations' efforts to upgrade the healthcare infrastructure will further impact the market dynamics by increasing funding. Another significant element influencing the growth rate of the market for chemotherapy is the rising cost of healthcare, which contributes to the development of its infrastructure. Government organizations' efforts to upgrade the healthcare infrastructure will further impact the market dynamics by increasing funding. Rising chemo awareness and an increase in patients undergoing these treatments are further factors expected to speed up the market's growth rate. Because of aging demographics, the demand for chemotherapeutic medications will also expand. Thus, driving the chemotherapy market revenue.

    Chemotherapy Market Segment Insights

    Chemotherapy Drug Class Insights

    The chemotherapy market segmentation, based on drug class, includes mitotic inhibitors, alkylating agents, antimetabolites, topoisomerase inhibitors and antitumor antibiotics. The alkylating agent segment dominated the market, accounting for 39.7% of market revenue (3.3 Billion). Alkylating substances result in DNA strand breakage, odd base pairing, or cross-linking of DNA strands, which prevents cell division. Generally speaking, alkylating chemicals are considered cell cycle phase nonspecific, meaning they can kill cells at different points in the cell cycle. The market for anti-metabolite drugs will expand dramatically as cancer rates increase globally. The anti-metabolite medication sector will also grow due to increased pipeline research and rising healthcare costs.

    Figure 2: Chemotherapy Market by Drug Class, 2023 & 2032 (USD Billion)

    Chemotherapy Market by Drug Class, 2022 & 2032

    Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

    Chemotherapy Indication Insights

    The chemotherapy market segmentation, based on indication, includes breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, lymphoma, leukemia and ovarian cancer. In 2022, leukemia dominated the market. Leukaemias with a sluggish growth rate may require monitoring as part of their treatment. Radiation therapy, stem cell transplant, and chemotherapy are sometimes used together to treat severe leukemias. Furthermore, the cases of breast cancer are also rising at a significant rate. The sector's growth is driven by the increasing prevalence of breast cancer in women, the variety of therapies available, and improved methods for breast cancer diagnostics using cutting-edge technologies.

    Chemotherapy Route of Drug Administration Insights

    The chemotherapy market segmentation, based on the route of drug administration, includes intravenous, oral, subcutaneous, intra-muscular, intravesicular, topical, intraperitoneal and intraventricular/intrathecal. The market's largest contributor, the oral category, is anticipated to expand at a major rate over the projected period. An oral cancer treatment drug is available as a pill, capsule, or liquid. However, the intravenous route witnessed the fastest growth rate. Since they are administered intravenously, chemotherapy drugs function more quickly than oral and topical treatments because they are instantly absorbed into the bloodstream.

    Chemotherapy End-User Insights

     The chemotherapy market segmentation, based on end-user, includes specialty centers and hospitals & clinics. The hospitals & clinics segment, dominated the market throughout the projected period. The precise cancer treatment provided in hospitals, the presence of qualified medical personnel, the availability of cutting-edge medical equipment, and favorable reimbursement rules are all associated with the sub-segments rapid rise. In 2022, specialty centers saw the fastest growth rate. Specialist centers are expected to be created due to several causes, including the rise in chronic illness cases, the expansion of public-private partnerships in the healthcare sector, and the growing senior population.

    Chemotherapy Regional Insights

    By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American chemotherapy market area will dominate this market. Multiple manufacturers of chemotherapy drugs and increased healthcare spending are North America's main market drivers. Accessibility to medical facilities and the application of cutting-edge technology in the study and treatment of cancer are other factors driving the market.

    Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

    Figure 2: CHEMOTHERAPY MARKET SHARE BY REGION 2023 (USD Billion)

    CHEMOTHERAPY MARKET SHARE BY REGION 2022

    Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

    Europe’s chemotherapy market accounts for the second-largest market share. The main drivers influencing the market's growth are the ease of regulatory approval for novel cancer therapies in Europe, the rising incidence of cancer, and significant R&D spending by the major companies in the market. According to data from 2021 provided by the International Agency for the Research on Cancer, there were 4.79 million cancer cases in the European region in 2020, and that number is projected to rise to 6.07 million by 2040. Further, the German chemotherapy market held the largest market share, and the UK chemotherapy market was the fastest-growing market in the European region

    The Asia-Pacific Chemotherapy Market is estimated to expand at a rapid rate from 2024 to 2032. It results from expanded government awareness initiatives and rising healthcare costs in this area. Due to the availability of trained and qualified healthcare providers and the rising need for chemotherapy drugs, the expanding accessibility of generic medications will also help to slow the market's rate of progress in this sector. Moreover, China’s chemotherapy market held the largest market share, and the Indian chemotherapy market was the fastest-growing market in the Asia-Pacific region.

    Chemotherapy Competitive Insights & Key Market Players

    Leading market players are largely investing in R&D to expand their production capacities, which will aid in the further expansion of the chemotherapy industry. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The chemotherapy industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

    One of the major business strategies manufacturers use in the chemotherapy industry to increase the market sector and benefit customers is local manufacturing to lower operational costs. Recently, the chemotherapy industry has stipulated some of the most important medicinal benefits. Major players in the chemotherapy market, including Pfizer Inc. (US), Sanofi S.A. (France), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson Services Inc (US), and others, are funding operations for research and development to boost market demand.

    Gland Pharma, founded in 1978 in Hyderabad, India, has evolved from a contract manufacturer [HK1] of small volume liquid parenteral products to one of the world's largest and fastest growing generic injectables manufacturing companies, with a footprint spanning 60 countries, including the Europe, United States, Canada, Australia, India, and other markets. In May 2022, Gland Pharma, in collaboration with a partner, released Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial in the US market. It is bioequivalent and therapeutically equivalent to Takeda Pharmaceuticals U.S.A., Inc.'s reference listed drug (RLD), Velcade for Injection, 3.5 mg/vial.

    AstraZeneca was created in 1999 by merging Astra of Sweden and Zeneca Group of the United Kingdom. The company sells branded medications in various therapeutic areas, including gastrointestinal, diabetic, cardiovascular, respiratory, cancer, immunology, and rare disorders. Most sales are done in foreign markets, with the United States making up nearly one-third of the total. In July 2021, AstraZeneca announced that the National Medical Products Administration (NMPA) had approved Imfinzi (durvalumab) for marketing in China for the medical management of patients with Stage III unresectable non-small cell lung cancer whose cancer did not advance following concurrent platinum-based chemotherapy and radiation therapy.

    Key Companies in the chemotherapy market include

      • Johnson & Johnson Services Inc (US)
      • GlaxoSmithKline PLC (UK)
      • Eli Lilly and Company (US)
      • F. Hoffmann-La Roche Ltd (Switzerland)
      • Novartis AG (Switzerland)
      • Pfizer Inc. (US)
      • Sanofi S.A. (France)
      • Celgene Corporation (US)

    Chemotherapy Industry Developments

    August 2022:Ipsen announced the completion of the definitive merger agreement that would see Ipsen acquire Epizyme, Inc. (Epizyme). Tazverik (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor awarded Accelerated Approval by US Food and Drug Administration in 2020, is acquired by Ipsen as part of the agreement.

    September 2020:Gilead Sciences Inc announced a $21 billion acquisition of Immunomedics Inc, boosting its cancer portfolio by obtaining access to a promising medicine. The agreement grants Gilead access to Immunomedics' breast cancer treatment medicine Trodelvy, which received fast FDA approval in April for an aggressive and difficult-to-treat kind of breast cancer.

    Chemotherapy Market Segmentation

    Chemotherapy Drug Class Outlook

      • Mitotic Inhibitors

      • Alkylating Agents

      • Antimetabolites

      • Topoisomerase Inhibitors

      • Antitumor Antibiotic

    Chemotherapy Indication Outlook

      • Breast Cancer

      • Lung Cancer

      • Colorectal Cancer

      • Prostate Cancer

      • Stomach Cancer

      • Lymphoma

      • Leukemia

      • Ovarian Cancer

    Chemotherapy Route of Drug Administration Outlook

      • Intravenous

      • Oral

      • Subcutaneous

      • Intra-Muscular

      • Intravesicular

      • Topical

      • Intraperitoneal

      • Intraventricular/Intrathecal

    Chemotherapy End-User Outlook

      • Specialty Centers

      • Hospitals & Clinics

    Chemotherapy Regional Outlook

      • North America

      • US

      • Canada

      • Europe

      • Germany

      • France

      • UK

      • Italy

      • Spain

      • Rest of Europe

      • Asia-Pacific

        • China

        • Japan

        • India

        • Australia

        • South Korea

        • Australia

        • Rest of Asia-Pacific

      • Rest of the World

        • Middle East

        • Africa

        • Latin America

    Market Size & Forecast

    Report Attribute/Metric Details
    Market Size 2023 USD 8.9 Billion
    Market Size 2024 USD 9.55 Billion
    Market Size 2032 USD 16.84 Billion
    Compound Annual Growth Rate (CAGR) 7.4% (2024-2032)
    Base Year 2023
    Market Forecast Period 2024-2032
    Historical Data 2018- 2022
    Market Forecast Units Value (USD Billion)
    Report Coverage Market Competitive Landscape, Growth Factors, Revenue Forecast, and Trends
    Segments Covered Drug Class, Route of Drug Administration, Indication, and End-User
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.
    Key Companies Profiled Pfizer Inc. (US), Sanofi S.A. (France), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson Services Inc (US).
    Key Market Opportunities Entering developing economies
    Key Market Dynamics Increasing prevalence of cancer

    Major Players

    Market Segmentation

    Chemotherapy Drug Class Outlook (USD Billion, 2018-2032)

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    Chemotherapy Indication Outlook (USD Billion, 2018-2032)

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    Chemotherapy Route of Drug Administration Outlook (USD Billion, 2018-2032)

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    Chemotherapy End-User Outlook (USD Billion, 2018-2032)

    • Specialty Centers

    • Hospitals & Clinics

    Chemotherapy Regional Outlook (USD Billion, 2018-2032)

    • North America Outlook (USD Billion, 2018-2032)

    • North America Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • North America Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • North America Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • North America Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • US Outlook (USD Billion, 2018-2032)

    • US Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • US Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • US Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • US Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • CANADA Outlook (USD Billion, 2018-2032)

    • CANADA Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • CANADA Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • CANADA Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • CANADA Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

    • Europe Outlook (USD Billion, 2018-2032)

    • Europe Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • Europe Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • Europe Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • Europe Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • Germany Outlook (USD Billion, 2018-2032)

    • Germany Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • Germany Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • Germany Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • Germany Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • France Outlook (USD Billion, 2018-2032)

    • France Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • France Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • France Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • France Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • UK Outlook (USD Billion, 2018-2032)

    • UK Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • UK Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • UK Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • UK Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • ITALY Outlook (USD Billion, 2018-2032)

    • ITALY Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • ITALY Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • ITALY Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • ITALY Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • SPAIN Outlook (USD Billion, 2018-2032)

    • SPAIN Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • SPAIN Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • SPAIN Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • SPAIN Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • Rest Of Europe Outlook (USD Billion, 2018-2032)

    • Rest Of Europe Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • Rest Of Europe Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • Rest Of Europe Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • Rest Of Europe Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

    • Asia-Pacific Outlook (USD Billion, 2018-2032)

    • Asia-Pacific Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • Asia-Pacific Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • Asia-Pacific Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • Asia-Pacific Chemotherapy by End-User

    • Specialty Centers

    • Hospitals & Clinics

      • China Outlook (USD Billion, 2018-2032)

    • China Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • China Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • China Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • China Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • Japan Outlook (USD Billion, 2018-2032)

    • Japan Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • Japan Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • Japan Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • Japan Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • India Outlook (USD Billion, 2018-2032)

    • India Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • India Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • India Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • India Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • Australia Outlook (USD Billion, 2018-2032)

    • Australia Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • Australia Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • Australia Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • Australia Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

    • Rest of Asia-Pacific Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • Rest of Asia-Pacific Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • Rest of Asia-Pacific Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • Rest of Asia-Pacific Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

    • Rest of the World Outlook (USD Billion, 2018-2032)

    • Rest of the World Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • Rest of the World Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • Rest of the World Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • Rest of the World Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • Middle East Outlook (USD Billion, 2018-2032)

    • Middle East Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • Middle East Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • Middle East Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • Middle East Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • Africa Outlook (USD Billion, 2018-2032)

    • Africa Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • Africa Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • Africa Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • Africa Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • Latin America Outlook (USD Billion, 2018-2032)

    • Latin America Chemotherapy by Drug Class

    • Mitotic Inhibitors

    • Alkylating Agents

    • Antimetabolites

    • Topoisomerase Inhibitors

    • Antitumor Antibiotic

    • Latin America Chemotherapy by Indication

    • Breast Cancer

    • Lung Cancer

    • Colorectal Cancer

    • Prostate Cancer

    • Stomach Cancer

    • Lymphoma

    • Leukemia

    • Ovarian Cancer

    • Latin America Chemotherapy by Route of Drug Administration

    • Intravenous

    • Oral

    • Subcutaneous

    • Intra-Muscular

    • Intravesicular

    • Topical

    • Intraperitoneal

    • Intraventricular/Intrathecal

    • Latin America Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

    Market Trends

    Global Chemotherapy Market Overview

    Chemotherapy Market Valued at USD 8.9 billion in 2023, projected to grow from USD 9.6 billion in 2024 to USD 16.84 billion by 2032, exhibiting a CAGR of 7.40% during the forecast period (2024 - 2032). 

    Factors such as rising cancer prevalence, an increase in the number of sufferers receiving chemotherapy and radiotherapy treatments, an increase in compliance with chemotherapy drugs due to various treatment options, and the availability of combination therapies are the key market drivers enhancing the market growth. The market for chemotherapy is anticipated to expand due to advances in drug delivery, development, and the shift toward biologics.

    Chemotherapy Market Overview

    Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

    Chemotherapy Market Trends

      • Growing cancer rates are fueling the market growth

    Market CAGR for chemotherapy is driven by the rising number of cancer patients. Cancer incidence has climbed globally, overtaking cardiovascular diseases as the second greatest cause of death. This phenomenon is caused by environmental variables such as cigarette use, altered dietary habits, urbanization, and prolonged post-reproductive lifetime. For instance, the World Heal...

    Market Segment Insights

    Smartphone Sensors Smartphone Type Insights

    The Smartphone Sensors market segmentation, based on smartphone type, includes standard smartphone, rugged smartphone, smartwatches, and other wearable. The standard smartphone segment dominated the market, accounting for the maximum market revenue. A smartphone is a mobile phone with a built-in computer and advanced features, such as web browsing and operating system, which are not associated with its counterpart. The rising mobile internet use, rising disposable income in developing countries, and high ownership of premium design smartphones are a few factors that are anticipated to grow smartphone sales. Smartphones are helped by a mobile operating system that offers advanced computing facilities. A smartphone can also work as a digital media player for uploading photos, videos, and music through a single interface.

    Smartphone Sensors Market, By Device Type Outlook, 2024 & 2035
    Get detailed insights about Chemotherapy Market

    Smartphone Sensors Manufacturer Insights

    The Smartphone Sensors market segmentation, based on the manufacturer, includes Apple Inc., Samsung Electronics, Huawei Technology, Xiaomi Inc., Oppo, Sony Corporation, HMD Global, and others. The Apple Inc. segment generated the most revenue due to its superior quality. Apple’s iPhone stands out over all other smartphones in the market. Apple Inc. is the market leader because they use more sensors in their devices to provide unique features. For Instance: Apple’s iPhone 12 uses a lidar for depth sensing, proximity for 3D touch, a gyroscope for compass, GPS, face ID for biometrics, auto-off, a barometer, a magnetometer for compass & GPS, and an ambient light sensor for auto-dimming displays. The better user experience, increased accessibility, and more security these sensors offer consumers to boost the segment‘s growth.

    Smartphone Sensors Application Insights

    The Smartphone Sensors market segmentation, based on the manufacturer, includes Apple Inc., Samsung Electronics, Huawei Technology, Xiaomi Inc., Oppo, Sony Corporation, HMD Global, and others. The Apple Inc. segment generated the most revenue due to its superior quality. Apple’s iPhone stands out over all other smartphones in the market. Apple Inc. is the market leader because they use more sensors in their devices to provide unique features. For Instance: Apple’s iPhone 12 uses a lidar for depth sensing, proximity for 3D touch, a gyroscope for compass, GPS, face ID for biometrics, auto-off, a barometer, a magnetometer for compass & GPS, and an ambient light sensor for auto-dimming displays. The better user experience, increased accessibility, and more security these sensors offer consumers to boost the segment‘s growth.

    Smartphone Sensors Regional Insights

    The Smartphone Sensors market segmentation, based on the manufacturer, includes Apple Inc., Samsung Electronics, Huawei Technology, Xiaomi Inc., Oppo, Sony Corporation, HMD Global, and others. The Apple Inc. segment generated the most revenue due to its superior quality. Apple’s iPhone stands out over all other smartphones in the market. Apple Inc. is the market leader because they use more sensors in their devices to provide unique features. For Instance: Apple’s iPhone 12 uses a lidar for depth sensing, proximity for 3D touch, a gyroscope for compass, GPS, face ID for biometrics, auto-off, a barometer, a magnetometer for compass & GPS, and an ambient light sensor for auto-dimming displays. The better user experience, increased accessibility, and more security these sensors offer consumers to boost the segment‘s growth.

    Smartphone Sensors Market, By Device Type Outlook, 2024 & 2035
    Get detailed insights about Smartphone Sensors Market

    Smartphone Sensors Price Insights

    The Smartphone Sensors market segmentation, based on price, includes USD 300 to USD 500, USD 100 to USD 300, above USD 500, and under USD 100. The USD 300 to USD 500 segment dominated the market revenue in the projected period. Most smartphones sold in medium-end devices have a sensor within this range. For instance: Nubia launched a new flagship Android device powered by the latest Snapdragon 8Gen 2CPU. The OEM has also specified that this gadget, which peculiarly seems to go by the name Z50 even though its processor was the z40 Pro, will compete with the Xiaomi 13 and iQOO11 series with cutting-edge LPDDR5X RAM and storage with the most recent UFS 4.0 spec.

    Get more detailed insights about Chemotherapy Market

    Key Players and Competitive Insights

    Leading market players are investing heavily in research and development to expand their product lines, which will help the Smartphone Sensors market, grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and growing market climate, the Smartphone Sensors industry must offer cost-effective items.

    Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Smartphone Sensors industry to benefit clients and increase the market sector. In recent years, the Smartphone Sensors industry has offered manufacturers some of the most significant advantages. Major players in the Smartphone Sensors market, including MS AG (Austria), Broadcom Inc. (US), DYNA IMAGE Corporation (China), Murata Electronics Oy (Finland), NEXT Biometrics Group ASA (Norway), Omron Corporation (Japan), Samsung Electronics Co. Ltd. (South Korea), Sony Corporation (Japan)., and others, are attempting to increase market demand by investing in research and development operations.

    Samsung is dedicated to abiding by local laws and regulations and enforcing a strict code of conduct for all employees. Samsung adheres to a straightforward business tent: to usage its technology and expertise to develop top-notch goods and services that make a more cultured world. Samsung provides a high importance on its people and technologies to do this. For Instance: In January 2023, Samsung Electronics launched its new MICRO LED, Neo QLED, and Samsung OLED product lines, along with lifestyle products and accessories, before CES® 2023.

    Apple Inc. is a multinational American technology business with its main office in Cupertino, California. According to revenue, Apple will be the top technological business in the world in 2022, with US $ 394.3 billion in sales. According to market capitalization, Apple is the largest corporation in the world as of March 2023. For Instance: In September 2022, the iPhone 14 and iPhone 14 Plus, which come in two sizes, 6.1 and 6.7 inches and include a smart design, camera upgrades, and game-changing new safety measures, were introduced by Apple. The iPhone 14 and iPhone 14 Plus have a powerful camera system that incorporates the primary and front TrueDepth cameras, the Ultra Wide camera for uncommon perspectives, and the photonic engine, an enhanced picture pipeline.

    Key Companies in the Smartphone Sensors market include

    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)

    Industry Developments

    • September 2022: Comcast and Samsung Electronics announced their partnership to create 5G Radio Access Network (RAN) technologies to enhance 5G connection for Xfinity Mobile and Comcast Business Mobile users in Comcast service zones. Samsung will provide 5G RAN technology, and Comcast will deploy Citizens Broadband Radio Service (CBRS) and 600 MHz spectrum to provide 5G access to consumer and business users in the US.
    • October 2022: Huawei announced the release of the newest antenna solutions, including the Maxwell platform and the X2 antenna series, for the subsequent 5G antenna innovation stage. The new technologies speed up 5G deployment by improving antenna and setup capabilities.

    Market Segmentation

    Smartphone Type Outlook

    • Standard Smartphone
    • Rugged Smartphone
    • Smartwatches
    • Other Wearable

    Price Outlook

    • USD 300 to USD 500
    • USD 100 to USD 300
    • Above USD 500
    • Under USD 100

    Manufacturer Outlook

    • Apple Inc.
    • Samsung Electronics
    • Huawei Technology
    • Xiaomi Inc.
    • Oppo
    • Sony Corporation
    • HMD Global

    Application Outlook

    • High-Level
    • Mid-Level
    • Low-Level

    Manufacturer Outlook

    North America
    • US
    • Canada
    Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
    Asia-Pacific
    • China
    • Japan
    • India
    • Italy
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    Rest of the World
    • Middle East
    • Africa
    • Latin America

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 USD 8.9 Billion
    Market Size 2024 USD 9.55 Billion
    Market Size 2032 USD 16.84 Billion
    Compound Annual Growth Rate (CAGR) 7.4% (2024-2032)
    Base Year 2023
    Market Forecast Period 2024-2032
    Historical Data 2018- 2022
    Market Forecast Units Value (USD Billion)
    Report Coverage Market Competitive Landscape, Growth Factors, Revenue Forecast, and Trends
    Segments Covered Drug Class, Route of Drug Administration, Indication, and End-User
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.
    Key Companies Profiled Pfizer Inc. (US), Sanofi S.A. (France), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson Services Inc (US).
    Key Market Opportunities Entering developing economies
    Key Market Dynamics Increasing prevalence of cancer

    Market Highlights

    Author

    Aarti Dhapte
    Team Lead - Research

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    What is the valuation of the Chemotherapy Market?

    Chemotherapy Market is expected to reach a valuation of close to USD 56.5 billion by 2024.

    What is the CAGR of the Chemotherapy Market?

    Chemotherapy Market is expected to exhibit a strong 11.5% CAGR over the forecast period from 2019 to 2024.

    What is the major driver for the Chemotherapy Market?

    The growing prevalence of cancer and the increasing use of chemotherapy in treating it is the major driver for the chemotherapy market.

    What is the leading regional market for chemotherapy?

    North America holds the largest share in the global chemotherapy market, although Europe and Asia Pacific also account for significant portions of the market.

    What are the leading players in the Chemotherapy Market?

    Leading players in the chemotherapy market include Johnson & Johnson Services, Bristol-Myers Squibb, GSK, Eli Lilly and Company, F. Hoffman-La Roche, Pfizer, Novartis, and Merck, among others.

    1. Research Methodology
      1. Research Process
      2. Primary Research 15
      3. Secondary Research 16
      4. Market Size
      5. Forecast Model 17
    2. Market Dynamics
      1. Introduction
      2. Drivers 19
        1. Increasing Prevalence of Cancer 19
        2. Reimbursements
      3. Restraints 20
        1. High Cost of Treatment
        2. Side-Effects of Chemotherapy 20
      4. Opportunities 20
    3. Market Factor Analysis
      1. Value Chain
        1. R&D and Designing 21
        2. Manufacturing 21
        3. Post-Sales Review 22
      2. Porter’s
        1. Bargaining Power of Suppliers 24
        2. Bargaining
        3. Threat of New Entrants 24
        4. Threat of Substitutes
        5. Intensity of Rivalry 24
      3. Investment Opportunities Analysis
      4. Pricing Analysis 25
      5. Chemotherapy Drugs by Route of Administration
      6. Chemotherapy Drugs by Indication 27
    4. Global Chemotherapy Market,
      1. Introduction 28
      2. Alkylating agents 29
      3. Mitotic
      4. Antimetabolites 30
      5. Topoisomerase Inhibitors 30
      6. Antitumor antibiotic 31
    5. Global Chemotherapy Market, by Indication
      1. Introduction 32
      2. Lung Cancer 33
      3. Breast Cancer 34
      4. Prostate Cancer 34
      5. Stomach Cancer 35
      6. Leukemia 35
      7. Ovarian Cancer 36
    6. Global Chemotherapy
      1. Intravenous 39
      2. Oral 39
      3. Intra-Muscular 40
      4. Intravesicular 40
      5. Topical
      6. Intraperitoneal 41
      7. Intraventricular/Intrathecal 41
    7. Global
      1. Introduction 42
      2. Specialty Centers
      3. Hospitals & Clinics 43
    8. Global Chemotherapy Market, by Region
      1. Introduction 44
      2. Americas 46
        1. North America 48
        2. South America 55
      3. Europe 57
        1. Eastern Europe 74
      4. Asia-Pacific 76
        1. Japan 79
        2. China 81
        3. India 83
        4. Australia 85
        5. South Korea
        6. Rest of Asia-Pacific 89
      5. Middle East & Africa 91
        1. Africa 95
    9. Competitive Landscape
      1. Company
    10. Company Profiles
      1. Johnson & Johnson Services
        1. Company Overview 100
        2. Financial Overview 100
        3. Products/Services Offered 101
        4. Key Developments 101
        5. Key Strategies 102
      2. GlaxoSmithKline PLC 103
        1. Company Overview 103
        2. Financial Overview 103
        3. Products/Services
        4. Key Developments 104
        5. SWOT Analysis 104
      3. Eli Lilly and Company 105
        1. Company Overview
        2. Financial Overview 105
        3. Products/Services Offered 106
        4. Key Developments 106
        5. SWOT Analysis 106
        6. Key Strategies
      4. F. Hoffmann-La Roche Ltd 107
        1. Company Overview 107
        2. Products/Services Offered 108
        3. Key
        4. SWOT Analysis 108
        5. Key Strategies 109
      5. Novartis AG 110
        1. Company Overview 110
        2. Financial Overview
        3. Products/Services Offered 111
        4. Key Developments 111
        5. SWOT Analysis 111
        6. Key Strategies 111
      6. Pfizer Inc.
        1. Company Overview 112
        2. Financial Overview 112
        3. Key Developments 113
        4. SWOT
        5. Key Strategies 113
      7. Merck & Co. Inc. 114
        1. Company Overview 114
        2. Financial Overview 114
        3. Products/Services
        4. Key Developments 115
        5. SWOT Analysis 115
      8. Sanofi S.A. 116
        1. Company Overview 116
        2. Financial Overview 116
        3. Products/Services Offered 117
        4. SWOT Analysis 118
        5. Key Strategies 118
      9. Celgene Corporation 119
        1. Company Overview 119
        2. Financial
        3. Products/Services Offered 120
        4. Key Developments
        5. SWOT Analysis 120
        6. Key Strategies 121
      10. Bristol-Myers
        1. Company Overview 122
        2. Financial Overview
        3. Products/Services Offered 123
        4. Key Developments 123
        5. SWOT Analysis 123
        6. Key Strategies 124
    11. Appendix
      1. References 125
      2. Related Reports 125
    12. List of Tables
    13. GLOBAL CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 29
    14. GLOBAL CHEMOTHERAPY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027
    15. NORTH AMERICA: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
    16. CANADA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 54
    17. EUROPE: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 59
    18. GERMANY: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 62
    19. ITALY: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 69
    20. EASTERN EUROPE: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
    21. ASIA-PACIFIC: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
    22. JAPAN: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 80
    23. INDIA: CHEMOTHERAPY MARKET, BY END USER, 2020–2027 (USD MILLION) 84
    24. SOUTH KOREA: CHEMOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027
    25. MIDDLE EAST & AFRICA: CHEMOTHERAPY MARKET, BY INDICATION, 2020–2027
    26. AFRICA: CHEMOTHERAPY MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION) 95
    27. List of Figures
    28. & 2027 (USD MILLION) 38

    Market Segmentation

    Chemotherapy Drug Class Outlook (USD Billion, 2018-2032)

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    Chemotherapy Indication Outlook (USD Billion, 2018-2032)

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    Chemotherapy Route of Drug Administration Outlook (USD Billion, 2018-2032)

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    Chemotherapy End-User Outlook (USD Billion, 2018-2032)

    • Specialty Centers
    • Hospitals & Clinics

    Chemotherapy Regional Outlook (USD Billion, 2018-2032)

    • North America Outlook (USD Billion, 2018-2032)

    • North America Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • North America Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • North America Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • North America Chemotherapy by End-User

    • Specialty Centers

        • Hospitals & Clinics

      • US Outlook (USD Billion, 2018-2032)

    • US Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • US Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • US Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • US Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • CANADA Outlook (USD Billion, 2018-2032)

    • CANADA Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • CANADA Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • CANADA Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • CANADA Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

    • Europe Outlook (USD Billion, 2018-2032)

    • Europe Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • Europe Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • Europe Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • Europe Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • Germany Outlook (USD Billion, 2018-2032)

    • Germany Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • Germany Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • Germany Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • Germany Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • France Outlook (USD Billion, 2018-2032)

    • France Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • France Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • France Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • France Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • UK Outlook (USD Billion, 2018-2032)

    • UK Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • UK Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • UK Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • UK Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • ITALY Outlook (USD Billion, 2018-2032)

    • ITALY Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • ITALY Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • ITALY Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • ITALY Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • SPAIN Outlook (USD Billion, 2018-2032)

    • SPAIN Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • SPAIN Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • SPAIN Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • SPAIN Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • Rest Of Europe Outlook (USD Billion, 2018-2032)

    • Rest Of Europe Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • Rest Of Europe Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • Rest Of Europe Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • Rest Of Europe Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

    • Asia-Pacific Outlook (USD Billion, 2018-2032)

    • Asia-Pacific Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • Asia-Pacific Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • Asia-Pacific Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • Asia-Pacific Chemotherapy by End-User

    • Specialty Centers
    • Hospitals & Clinics

      • China Outlook (USD Billion, 2018-2032)

    • China Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • China Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • China Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • China Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • Japan Outlook (USD Billion, 2018-2032)

    • Japan Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • Japan Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • Japan Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • Japan Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • India Outlook (USD Billion, 2018-2032)

    • India Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • India Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • India Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • India Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • Australia Outlook (USD Billion, 2018-2032)

    • Australia Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • Australia Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • Australia Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • Australia Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

    • Rest of Asia-Pacific Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • Rest of Asia-Pacific Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • Rest of Asia-Pacific Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • Rest of Asia-Pacific Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

    • Rest of the World Outlook (USD Billion, 2018-2032)

    • Rest of the World Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • Rest of the World Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • Rest of the World Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • Rest of the World Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • Middle East Outlook (USD Billion, 2018-2032)

    • Middle East Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • Middle East Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • Middle East Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • Middle East Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • Africa Outlook (USD Billion, 2018-2032)

    • Africa Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • Africa Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • Africa Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • Africa Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics

      • Latin America Outlook (USD Billion, 2018-2032)

    • Latin America Chemotherapy by Drug Class

    • Mitotic Inhibitors
    • Alkylating Agents
    • Antimetabolites
    • Topoisomerase Inhibitors
    • Antitumor Antibiotic

    • Latin America Chemotherapy by Indication

    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Lymphoma
    • Leukemia
    • Ovarian Cancer

    • Latin America Chemotherapy by Route of Drug Administration

    • Intravenous
    • Oral
    • Subcutaneous
    • Intra-Muscular
    • Intravesicular
    • Topical
    • Intraperitoneal
    • Intraventricular/Intrathecal

    • Latin America Chemotherapy by End-User

    • Specialty Centers
        • Hospitals & Clinics
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    Global Reports
    Regional Reports
    Country Reports

    Customer Strories

    Watch Video

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Jongwon Byun

    Director, Research Operations
    Case Study

    Smartphone Motherboard Parts Manufacturing Research

    Smartphone Motherboard Parts Manufacturing Research